Genmab A/S Sponsored ADR GMAB

Genmab A/S expects three pivotal Phase III readouts in Q4: EPKINLY plus R-CHOP in frontline DLBCL; Rina-S in platinum-resistant ovarian cancer; and petosemtamab plus KEYTRUDA in first-line metastatic head and neck cancer. All three are viewed as potentially first-in-class, with broad development plans including additional Phase III trials in gynecologic, colorectal and head and neck cancers. If data and regulatory reviews are favorable, launches could occur in 2027. Petosemtamab is projected to exceed $1 billion in sales by 2029, with multi-billion-dollar peak potential. VP/investor relations head Andrew Carlsen said the company had a strong first half and raised guidance, aided by DARZALEX and EPKINLY. Data on petosemtamab in colorectal cancer will be presented at the ESMO congress in late October." Three Phase III readouts and potential 2027 launches for multiple assets could materially shift Genmab's growth trajectory.

Genmab's CPSE:GMAB ADR fair value target was cut to DKK 2,303.24 from DKK 2,453.79 as analysts weigh pipeline upside against concentration risk and the US$3.6 billion Darzalex patent cliff. Bulls flag Epkinly, rinatabart sesutecan, and petosemtamab as potential offsets and note EPCORE DLBCL-4 results; bears point to valuation risk and mixed sentiment, with Morgan Stanley maintaining Equal Weight. Several firms raise targets (TD Cowen, H.C. Wainwright, Guggenheim, Deutsche Bank, William Blair). The fair value update also incorporates modest changes to revenue growth assumptions (16.0%), net margin (25.85%), forward P/E (13.80x), and discount rate (6.16%). The piece frames Genmab's upside from pipeline against Darzalex's patent cliff and pricing/regulatory risks. Fair value trimmed amid pipeline risks and Darzalex patent cliff, with some upside from Epkinly and other assets.

Genmab royalty growth is positioned to drive a new earnings cycle and lift GMAB stock performance. Royalty expansion directly supports a new earnings cycle that can materially shift GMAB trajectory and sentiment.

Genmab A/S faces a new regulatory test for Epcoritamab, prompting questions on whether AbbVie Inc. could gain from the outcome. Regulatory test for Epcoritamab introduces risks that could shift Genmab market position relative to AbbVie.

Genmab A/S Sponsored ADR stock rose 4.4% after drug royalties lifted the company's outlook. Drug royalties improve Genmab financial outlook and support stock gains.

Genmab A/S Sponsored ADR (GMAB) held Q2 2026 earnings call discussing financial results, business updates and outlook. Quarterly earnings call delivers performance metrics and guidance with moderate effects on stock trajectory.

Genmab AS posted strong revenue growth in its Q2 2026 earnings call alongside strategic updates. Earnings results with revenue growth and strategic items can moderately affect near-term sentiment and valuation but rarely shift long-term trajectory alone.

Genmab A/S Q2 earnings call highlighted financial performance, product developments, and strategic initiatives for the period. Q2 earnings updates provide moderate insight into financial results and outlook without major strategic shifts.

Genmab A/S Sponsored ADR (GMAB) announced financial results for the first half of 2026. Half-year financial results release can moderately sway investor views on performance.

Epcoritamab trial setback leads to AbbVie (ABBV) potentially being 3% undervalued, with direct effects on partner Genmab (GMAB) via their shared bispecific antibody program. Epcoritamab setback hits a core Genmab asset and AbbVie partnership but market reaction appears contained to modest valuation adjustment.

Genmab and AbbVie clarified details of the Phase 3 EPCORE DLBCL-1 trial testing epcoritamab in relapsed/refractory DLBCL patients. Clarification on phase 3 trial progress for lead asset epcoritamab can shift near-term sentiment around Genmab's pipeline.

Genmab and AbbVie clarified details of the Phase 3 EPCORE DLBCL-1 trial testing epcoritamab in relapsed/refractory DLBCL patients. Clarification on epcoritamab Phase 3 trial progress can moderately shift Genmab development outlook and sentiment.

Genmab announced net sales of DARZALEX for the second quarter of 2026. Quarterly DARZALEX sales updates provide direct insight into Genmab's main revenue driver and can shift near-term sentiment.

Positive Epkinly DLBCL trial results prompt evaluation of Genmab A/S Sponsored ADR (GMAB) stock valuation. Positive Epkinly DLBCL trial data strengthen Genmab oncology pipeline and revenue outlook.

Genmab's TEPKINLY (epcoritamab) combined with lenalidomide and rituximab receives European Commission approval for treating relapsed or refractory follicular lymphoma. European approval of epcoritamab combination expands Genmab's market access and revenue potential in lymphoma treatment.

Genmab receives European Commission approval for TEPKINLY (epcoritamab) combined with lenalidomide and rituximab to treat relapsed or refractory follicular lymphoma. European approval expands TEPKINLY use in follicular lymphoma and is likely to boost revenue and market position.

Genmab announces positive Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory diffuse large B-cell lymphoma, demonstrating statistically significant improvement in progression-free survival. Positive Phase 3 data for lead oncology asset strengthens regulatory and commercial outlook.

Genmab announces positive Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory diffuse large B-cell lymphoma, showing statistically significant improvement in progression-free survival. Positive Phase 3 data for epcoritamab combination strengthens approval prospects and revenue potential in major lymphoma indication.

Genmab's EPCORE data strengthens lymphoma treatment profile as investors assess upside potential for GMAB. EPCORE lymphoma data directly supports Genmab oncology positioning and can materially shift investor views.

Genmab reports high response rates for epcoritamab monotherapy and epcoritamab-based combinations in elderly patients with newly diagnosed diffuse large B-cell lymphoma. Positive epcoritamab data in frontline DLBCL expands addressable market for Genmab's lead asset.

Genmab presented EPCORE FL-1 subgroup data confirming consistent efficacy and safety of epcoritamab plus rituximab and lenalidomide across relapsed or refractory follicular lymphoma patients. Positive subgroup data on epcoritamab combination strengthens development prospects and market positioning in follicular lymphoma.

Genmab presents EPCORE FL-1 subgroup data confirming consistent efficacy and safety for epcoritamab plus R2 regimen in relapsed or refractory follicular lymphoma patients. Positive subgroup data on epcoritamab combination advances pipeline visibility but remains early-stage without immediate revenue impact.

Genmab share price softness follows recent trading while valuation estimates indicate 24.6 percent undervaluation. Valuation estimate of 24.6 percent undervaluation may lift near-term investor sentiment and share demand.

Genmab A/S Sponsored ADR (GMAB) announces major shareholder update. Major shareholder announcements often affect ownership stakes and investor sentiment without fundamentally altering core operations.

Genmab A/S Q1 earnings call highlights key financial results, pipeline progress including epcoritamab advancements, R&D updates, and reaffirmed 2024 guidance amid strong revenue growth from royalty and milestone income. Q1 earnings highlights reveal strong revenue growth, positive clinical data, and reaffirmed guidance, likely boosting investor confidence and stock trajectory.

Genmab’s Q1 revenue rose sharply, propelled by higher DARZALEX royalties, as the company advances its expansion strategy. Strong Q1 revenue growth from DARZALEX royalties enhances financial performance and supports strategic expansion, significantly influencing future trajectory.

Genmab A/S Sponsored ADR (GMAB) announced financial results for the first quarter of 2026. Q1 2026 financial results represent a major update on revenue, profitability, and guidance that can significantly sway investor sentiment and stock trajectory.

Genmab (GMAB) receives Outperform rating from analysts citing its strong oncology pipeline. Outperform rating on core oncology pipeline boosts investor sentiment and signals significant growth potential for GMAB.

Goldman Sachs lifted its rating on Genmab A/S Sponsored ADR (GMAB) citing strong 2026 catalyst outlook. Goldman Sachs rating upgrade signals strong 2026 catalysts, poised to significantly enhance investor sentiment and GMAB's market trajectory.

Genmab A/S Sponsored ADR (GMAB) stock rises after Goldman Sachs upgrades it to Buy, citing increased confidence in the company's pipeline. Goldman Sachs' upgrade to Buy on stronger pipeline confidence boosts investor sentiment and signals significant positive impact on GMAB's stock trajectory.